Why the study?
Does intravenous UK-68,798 prolong the QT interval and exhibit predictable pharmacokinetics in healthy volunteers?
Population
12 healthy volunteers
Comparison
UK-68,798 administered intravenously at doses of… vs Placebo
Design
RCT, double-blind
Authors
Loading...
Alerts clinicians to QT monitoring needs; confirms selective class III activity and supports arrhythmia trials.
Does intravenous UK-68,798 prolong the QT interval and exhibit predictable pharmacokinetics in healthy volunteers?
UK-68,798 demonstrates selective class III anti-arrhythmic activity by prolonging the QT interval with predictable, dose-independent pharmacokinetics in healthy volunteers.
Gemmill et al. (1991) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: